Biochemistry and
Biotechnology Professionals
Society of Kenya (BBPSK)
Scientists at the Lewis Katz School of Medicine at Temple University have developed a groundbreaking CRISPR gene-editing treatment, EBT-001, that has successfully and safely removed SIV (a virus similar to HIV) from the genomes of non-human primates. The study, published in the journal Gene Therapy, demonstrated that a single injection of EBT-001 effectively excised SIV from viral reservoirs in rhesus macaques without any detectable off-target effects. This significant preclinical achievement has led to the ongoing clinical trials of EBT-101, an HIV-specific gene-editing therapy, in humans, which was authorized by the FDA in 2022. The treatment showed no evidence of toxicity and was well-tolerated by the animals, reaching tissues throughout the body.
You can find the full article here: Novel Treatment Based on Gene Editing Safely and Effectively Removes HIV Virus Genomes in Non-Human Primates